<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05622578</url>
  </required_header>
  <id_info>
    <org_study_id>APHP220664</org_study_id>
    <secondary_id>2022-A01357-36</secondary_id>
    <nct_id>NCT05622578</nct_id>
  </id_info>
  <brief_title>Phenotyping of Chronic Pain in Diffused Systemic Scleroderma</brief_title>
  <acronym>PAIN SSc</acronym>
  <official_title>Phenotyping of Chronic Pain in Diffused Systemic Scleroderma: Characteristics and Perturbations of Mechanisms of Pain, Impact on the Quality of Life and Correlations of Fatigue, Sleeping Disorders and Mood or Anxiety Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association de patients : association sclérodermies de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to describe the different phenotyping of pain in&#xD;
      systemic scleroderma patients and perturbations of mechanisms of the pain.&#xD;
&#xD;
      As secondary objectives, the study aims to describe the importances of overall symptoms in&#xD;
      alteration of quality of life and conserve the questions which will be associated in a unique&#xD;
      questionnaire in order to evaluate the pain, the fatigue and the sleeping disorders in&#xD;
      diffused systemic scleroderma patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, controlled study.&#xD;
&#xD;
      Beside the routine care, the patients will have only one visit in the study during which the&#xD;
      informed consent will be signed, also the following will be performed: pain evaluation, blood&#xD;
      sampling, questionnaires and Sudoscan, test QST.&#xD;
&#xD;
      100 patients will be enrolled in total with 50 in each group (scleroderma with pain vs.&#xD;
      scleroderma without pain, 1:1 ratio), the duration of inclusion is estimated for 23 months.&#xD;
&#xD;
      2 centers will be involved in the enrollment of patients: rheumatology department and interne&#xD;
      medicine department of Cochin hospital-APHP. One center will perform the evaluations of pain&#xD;
      for all patients: center of pain of Cochin hospital - APHP.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2022</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pain</measure>
    <time_frame>at baseline</time_frame>
    <description>McGill Pain Questionnaire (MPQ) will be used.&#xD;
McGill Pain Questionnaire is a self-report questionnaire for multidimensional pain assessment in chronic pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pain by NRS</measure>
    <time_frame>at baseline</time_frame>
    <description>Pain will be evaluated by the numerical pain rating scale (NRS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pain by BPI</measure>
    <time_frame>at baseline</time_frame>
    <description>Pain will be evaluated by the Brief Pain Inventory (BPI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pain by DN4</measure>
    <time_frame>at baseline</time_frame>
    <description>Pain will be evaluated by the Douleur Neuropathique (DN4) questionnaire as tool.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pain by Pain Detect Questionnaires</measure>
    <time_frame>at baseline</time_frame>
    <description>Pain will be evaluated by the painDETECT questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of pain by FiRST</measure>
    <time_frame>at baseline</time_frame>
    <description>Pain will be evaluated by the Fibromyalgia Rapid Screening Tool (FiRST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life by questionnaire EQ5D</measure>
    <time_frame>at baseline</time_frame>
    <description>By questionnaire EQ5D.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of quality of life by questionnaire HAQ.</measure>
    <time_frame>at baseline</time_frame>
    <description>By questionnaire HAQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SSc-SAQ questionnaire development</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Questionnaire of symptoms associated with SSc.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Scleroderma, Systemic</condition>
  <condition>Scleroderma, Diffuse</condition>
  <arm_group>
    <arm_group_label>scleroderma with pain</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>systemic sclerosis (SSc) with chronic pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>scleroderma without pain</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>systemic sclerosis patients without chronic pain</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>QST, CPM and Paisudoscan</intervention_name>
    <description>Quantified pain tests</description>
    <arm_group_label>scleroderma with pain</arm_group_label>
    <arm_group_label>scleroderma without pain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years;&#xD;
&#xD;
          -  Patients with diffused SSc according to ACR / EULAR Classification 2013 since at least&#xD;
             3 months;&#xD;
&#xD;
          -  For group pain: pain intensity ≥4 of 11 points of scale (NRS);&#xD;
&#xD;
          -  For group painless: pain intensity on the month before inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to understand french language;&#xD;
&#xD;
          -  Patients no-affiliated to the french social security scheme;&#xD;
&#xD;
          -  Patients under the french AME scheme;&#xD;
&#xD;
          -  Patients under guardianship;&#xD;
&#xD;
          -  Pregnant and breastfeeding patients;&#xD;
&#xD;
          -  Patients with thermoalgesic neuropathy;&#xD;
&#xD;
          -  Articular pain from degenerative diseases (known osteoarthritis);&#xD;
&#xD;
          -  Patients under antidepressant;&#xD;
&#xD;
          -  Temporary discontinuation of analgesics which are not well tolerated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge PERROT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center of evaluation and treatment of pain - Cochin hospital - APHP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Priscille TROUVIN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Center of evaluation and treatment of pain - Cochin hospital - APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Serge PERROT, MD, PhD</last_name>
    <phone>+ 33 01 58 41 30 40</phone>
    <email>Serge.perrot@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Priscille TROUVIN, MD</last_name>
    <phone>+ 33 01 58 41 30 40</phone>
    <email>annepriscille.trouvin@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center of evaluation and treatment of pain - Cochin hospital - APHP</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>September 26, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scleroderma</keyword>
  <keyword>phenotyping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

